Management of the female HIV-infected patient.

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Management of the female HIV-infected patient.

AIDS Res Hum Retroviruses. 1994 Aug;10(8):935-8. Unique Identifier : AIDSLINE MED/95110639
Baker DA; Department of Obstetrics and Gynecology, HSC State University of; New York at Stony Brook 11794-8091.

Abstract: Management of women with HIV infection or AIDS should follow the established guidelines for antiretroviral therapy and prevention and treatment of opportunistic complications of HIV infection. Gynecological manifestations of HIV are primarily cervical dysplasia and cancer associated with human papillomavirus (HPV) infection and vaginal and mucocutaneous candidiasis. Human papillomavirus-associated cervical dysplasia/neoplasia is more common in women with advanced rather than early HIV disease, and monitoring with Pap smears should probably increase to every 6 months in patients with CD4+ cell counts < 500 cells/microliter (and certainly when this value falls below 200), with positive Pap smears confirmed by colposcopy and biopsy. For patients with CD4+ cell counts > 350 cells/microliter, cryotherapy is probably adequate, but therapy should be increasingly aggressive at lower CD4+ cell counts. Results of ongoing studies should be available soon to guide therapy. Optimal treatment of candidiasis in HIV-infected women includes prevention of recurrence with a combination of topical and systemic antifungal agents. Women with child-bearing potential should be treated as medically indicated for other HIV-infected patients, including during pregnancy. In fact, preliminary results of ACTG 076 indicated that zidovudine therapy during pregnancy reduces vertical transmission of HIV about threefold.

Keywords: AIDS-Related Opportunistic Infections/*DRUG THERAPY/*PREVENTION & CONTROL Candidiasis, Cutaneous/DRUG THERAPY Candidiasis, Vulvovaginal/DRUG THERAPY Female Genital Diseases, Female/*DRUG THERAPY Human HIV Infections/*DRUG THERAPY Infant, Newborn Papovaviridae Infections/DRUG THERAPY Pregnancy Pregnancy Complications, Infectious/*DRUG THERAPY Tumor Virus Infections/DRUG THERAPY JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL
950430
M9540755

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .